JPWO2020002063A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020002063A5 JPWO2020002063A5 JP2020560739A JP2020560739A JPWO2020002063A5 JP WO2020002063 A5 JPWO2020002063 A5 JP WO2020002063A5 JP 2020560739 A JP2020560739 A JP 2020560739A JP 2020560739 A JP2020560739 A JP 2020560739A JP WO2020002063 A5 JPWO2020002063 A5 JP WO2020002063A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- peptide
- cell
- fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011510 cancer Diseases 0.000 claims 34
- 210000004027 cells Anatomy 0.000 claims 31
- 108090001123 antibodies Proteins 0.000 claims 27
- 102000004965 antibodies Human genes 0.000 claims 27
- 108091008153 T cell receptors Proteins 0.000 claims 23
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 17
- 239000011780 sodium chloride Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 16
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 14
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 11
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 230000027455 binding Effects 0.000 claims 9
- 108020001507 fusion proteins Proteins 0.000 claims 8
- 102000037240 fusion proteins Human genes 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims 7
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 6
- 229920002395 Aptamer Polymers 0.000 claims 6
- 210000000941 Bile Anatomy 0.000 claims 6
- 210000000013 Bile Ducts Anatomy 0.000 claims 6
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 6
- 206010017758 Gastric cancer Diseases 0.000 claims 6
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 6
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 6
- 206010033128 Ovarian cancer Diseases 0.000 claims 6
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 6
- 206010060862 Prostate cancer Diseases 0.000 claims 6
- 239000002671 adjuvant Substances 0.000 claims 6
- 230000000240 adjuvant Effects 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000004101 esophageal cancer Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 201000002528 pancreatic cancer Diseases 0.000 claims 6
- 201000011549 stomach cancer Diseases 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 208000009956 Adenocarcinoma Diseases 0.000 claims 5
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 5
- 206010025650 Malignant melanoma Diseases 0.000 claims 5
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 5
- 201000001441 melanoma Diseases 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 5
- 210000001519 tissues Anatomy 0.000 claims 5
- 206010014733 Endometrial cancer Diseases 0.000 claims 4
- 208000005017 Glioblastoma Diseases 0.000 claims 4
- 206010046766 Uterine cancer Diseases 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 108091007172 antigens Proteins 0.000 claims 4
- 102000038129 antigens Human genes 0.000 claims 4
- 238000002659 cell therapy Methods 0.000 claims 4
- 230000000875 corresponding Effects 0.000 claims 4
- 239000012528 membrane Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229960005486 vaccines Drugs 0.000 claims 4
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims 3
- 102000015696 Interleukins Human genes 0.000 claims 3
- 108010063738 Interleukins Proteins 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000011231 colorectal cancer Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 210000004291 Uterus Anatomy 0.000 claims 2
- 239000003139 biocide Substances 0.000 claims 2
- 230000022534 cell killing Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000032 diagnostic agent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000002357 endometrial Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000000546 pharmaceutic aid Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000010186 staining Methods 0.000 claims 2
- 210000004907 Glands Anatomy 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 102000006354 HLA-DR Antigens Human genes 0.000 claims 1
- 108010058597 HLA-DR Antigens Proteins 0.000 claims 1
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims 1
- 210000003494 Hepatocytes Anatomy 0.000 claims 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000003308 immunostimulating Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 230000003834 intracellular Effects 0.000 claims 1
- 108010028930 invariant chain Proteins 0.000 claims 1
- 230000003278 mimic Effects 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000000268 renotropic Effects 0.000 claims 1
- 210000004085 squamous epithelial cell Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692348P | 2018-06-29 | 2018-06-29 | |
| DE102018115865.3A DE102018115865A1 (de) | 2018-06-29 | 2018-06-29 | A*03-restringierte Peptide zur Verwendung in der Immuntherapie gegen Krebs und verwandte Verfahren |
| US62/692,348 | 2018-06-29 | ||
| DE102018115865.3 | 2018-06-29 | ||
| DE102018116584.6 | 2018-07-09 | ||
| DE102018116584 | 2018-07-09 | ||
| US16/030,725 US10925947B2 (en) | 2018-06-29 | 2018-07-09 | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| US16/030,725 | 2018-07-09 | ||
| PCT/EP2019/066115 WO2020002063A1 (fr) | 2018-06-29 | 2019-06-19 | Peptides restreints a*03 destinés à être utilisés en immunothérapie contre des cancers et procédés associés |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021528046A JP2021528046A (ja) | 2021-10-21 |
| JPWO2020002063A5 true JPWO2020002063A5 (fr) | 2022-06-28 |
Family
ID=67070807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560739A Pending JP2021528046A (ja) | 2018-06-29 | 2019-06-19 | がんに対する免疫療法で使用するためのａ＊０３拘束性ペプチドおよび関連方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (12) | US10925947B2 (fr) |
| EP (1) | EP3813873A1 (fr) |
| JP (1) | JP2021528046A (fr) |
| KR (1) | KR20210025534A (fr) |
| CN (2) | CN113444148A (fr) |
| AU (1) | AU2019294731A1 (fr) |
| BR (1) | BR112020022250A2 (fr) |
| CA (1) | CA3097698A1 (fr) |
| CL (4) | CL2020003371A1 (fr) |
| CO (1) | CO2020013659A2 (fr) |
| CR (1) | CR20200632A (fr) |
| IL (1) | IL279843A (fr) |
| MA (1) | MA53004A (fr) |
| MX (1) | MX2020012257A (fr) |
| PE (1) | PE20211499A1 (fr) |
| PH (1) | PH12020552013A1 (fr) |
| SG (1) | SG11202009659XA (fr) |
| TW (1) | TW202019462A (fr) |
| WO (1) | WO2020002063A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111548405A (zh) * | 2017-04-10 | 2020-08-18 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的肽及其肽组合物 |
| IL296881A (en) * | 2020-04-14 | 2022-12-01 | Universit? De Montr?Al | New antigens specific for acute myeloid leukemia (aml) and their uses |
| WO2024077601A1 (fr) * | 2022-10-14 | 2024-04-18 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Vaccins peptidiques contre le gliome et leurs utilisations |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| YU44186B (en) | 1978-12-22 | 1990-04-30 | Biogen Nv | Process for obtaining recombinant dnk molecules |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| GB2294267B (en) | 1993-06-03 | 1996-11-20 | Therapeutic Antibodies Inc | Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US5807978A (en) | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
| ATE244300T1 (de) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| AUPO500997A0 (en) * | 1997-02-07 | 1997-03-06 | Macquarie Research Limited | Diagnosis of disease using tears |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20070020327A1 (en) * | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| JP2004503213A (ja) | 2000-03-27 | 2004-02-05 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | １本鎖クラスｉ主要組織適合性複合体、それをコードする構築物およびそれを生成する方法 |
| AU2001275246B2 (en) | 2000-06-05 | 2006-06-29 | Altor Bioscience Corporation | T cell receptor fusions and conjugates and methods of use thereof |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (fr) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Ligands de liaison au complexe mhc-peptide |
| WO2004033685A1 (fr) | 2002-10-09 | 2004-04-22 | Avidex Ltd | Recepteurs de lymphocytes t de recombinaison a chaine unique |
| DK1558643T3 (da) | 2002-11-09 | 2009-09-07 | Immunocore Ltd | Cellereceptorpr sentation |
| US20060094649A1 (en) * | 2002-12-10 | 2006-05-04 | Keogh Elissa A | Hla-a1,-a2,-a3,-a24,-b7, and-b44 tumor associated antigen peptides and compositions |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| ATE461214T1 (de) | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| DK2207564T3 (en) * | 2007-10-18 | 2017-01-16 | Bavarian Nordic As | USE OF VAT FOR TREATMENT OF PROSTATACANCES |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
| US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CA2816225A1 (fr) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Anticorps qui se lient a des ligands de recepteurs de lymphocytes t solubles |
| WO2013057586A1 (fr) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions et procédés de production de récepteurs solubles des lymphocytes t |
| ES2603589T3 (es) | 2012-11-08 | 2017-02-28 | F. Hoffmann-La Roche Ag | Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas |
| EP2808392A1 (fr) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamères et utilisation de ces aptamères dans le diagnostic et le traitement du cancer |
| TWI777197B (zh) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（六） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201411037D0 (en) * | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| MA41217A (fr) * | 2014-12-19 | 2017-10-24 | Advaxis Inc | Polythérapies ayant des souches de listeria recombinées |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| CN108513593A (zh) * | 2015-04-23 | 2018-09-07 | 南托米克斯有限责任公司 | 癌症新表位 |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017089786A1 (fr) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
| CA3006759A1 (fr) | 2015-11-30 | 2017-06-08 | The Regents Of The University Of California | Administration de charge utile specifique de tumeur et activation immunitaire au moyen d'un anticorps humain ciblant un antigene de surface de cellule tumorale tres specifique |
| WO2019008001A1 (fr) | 2017-07-04 | 2019-01-10 | Curevac Ag | Nouvelles molécules d'acide nucléique |
| AU2018395397A1 (en) * | 2017-12-28 | 2020-08-06 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
-
2018
- 2018-07-09 US US16/030,725 patent/US10925947B2/en active Active
-
2019
- 2019-06-19 JP JP2020560739A patent/JP2021528046A/ja active Pending
- 2019-06-19 CN CN202110718511.7A patent/CN113444148A/zh active Pending
- 2019-06-19 BR BR112020022250-0A patent/BR112020022250A2/pt unknown
- 2019-06-19 KR KR1020207037583A patent/KR20210025534A/ko unknown
- 2019-06-19 PE PE2020002193A patent/PE20211499A1/es unknown
- 2019-06-19 AU AU2019294731A patent/AU2019294731A1/en active Pending
- 2019-06-19 SG SG11202009659XA patent/SG11202009659XA/en unknown
- 2019-06-19 WO PCT/EP2019/066115 patent/WO2020002063A1/fr active Application Filing
- 2019-06-19 MX MX2020012257A patent/MX2020012257A/es unknown
- 2019-06-19 CA CA3097698A patent/CA3097698A1/fr active Pending
- 2019-06-19 US US16/446,384 patent/US10946081B2/en active Active
- 2019-06-19 EP EP19733696.9A patent/EP3813873A1/fr active Pending
- 2019-06-19 CR CR20200632A patent/CR20200632A/es unknown
- 2019-06-19 CN CN201980044402.2A patent/CN112399853A/zh active Pending
- 2019-06-19 MA MA053004A patent/MA53004A/fr unknown
- 2019-06-28 TW TW108122776A patent/TW202019462A/zh unknown
-
2020
- 2020-05-29 US US16/887,815 patent/US10828357B2/en active Active
- 2020-06-30 US US16/917,381 patent/US10869917B2/en active Active
- 2020-10-29 CO CONC2020/0013659A patent/CO2020013659A2/es unknown
- 2020-11-24 PH PH12020552013A patent/PH12020552013A1/en unknown
- 2020-12-23 CL CL2020003371A patent/CL2020003371A1/es unknown
- 2020-12-29 IL IL279843A patent/IL279843A/en unknown
-
2021
- 2021-01-14 US US17/149,381 patent/US11058755B2/en active Active
- 2021-01-14 US US17/149,397 patent/US11872270B2/en active Active
- 2021-01-14 US US17/149,241 patent/US11833193B2/en active Active
- 2021-07-02 US US17/366,885 patent/US20210330771A1/en active Pending
- 2021-07-02 US US17/366,958 patent/US11246917B2/en active Active
-
2022
- 2022-07-19 US US17/868,368 patent/US11554164B2/en active Active
- 2022-07-29 US US17/876,899 patent/US11576955B2/en active Active
- 2022-11-30 CL CL2022003382A patent/CL2022003382A1/es unknown
- 2022-11-30 CL CL2022003380A patent/CL2022003380A1/es unknown
- 2022-11-30 CL CL2022003381A patent/CL2022003381A1/es unknown
-
2023
- 2023-01-27 US US18/160,420 patent/US20230226162A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020191862A5 (fr) | ||
| JP2020182458A5 (fr) | ||
| JP2020198875A5 (fr) | ||
| JP2020516681A5 (fr) | ||
| JP2019511214A5 (fr) | ||
| JP2021168652A5 (fr) | ||
| JP2018529320A5 (fr) | ||
| JP2018510628A5 (fr) | ||
| JP2019502360A5 (fr) | ||
| JP2021101700A5 (fr) | ||
| JP2019510465A5 (fr) | ||
| JP2019506838A5 (fr) | ||
| CN114127091B (zh) | 肿瘤新抗原多肽及其用途 | |
| JP2018519243A5 (fr) | ||
| JP2018518937A5 (fr) | ||
| JP2019516663A5 (fr) | ||
| JP2018509135A5 (fr) | ||
| JP2017502076A5 (fr) | ||
| HRP20202019T1 (hr) | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora | |
| JP2018511321A5 (fr) | ||
| RU2017137142A (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| CN109400713A (zh) | 新型嵌合抗原受体修饰的t细胞治疗癌症的用途 | |
| JP2017525336A5 (fr) | ||
| JP2019515653A5 (fr) | ||
| JP2020530759A5 (fr) |